| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-316.52美元,归母净利润-2526.3万美元,同比去年增长27.68%
|
| 2024-01-30 |
详情>>
股本变动：
变动后总股本4423.02万股
变动原因 ▼▲
- 原因：
- Common stock offered 4,375,0000 shares by the company
|
| 2024-01-26 |
复牌提示：
2024-01-26 09:38:21 停牌，复牌日期 2024-01-26 09:43:21
|
| 2024-01-18 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-11-24 |
股东大会：
将于2023-12-19召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our outstanding common stock, par value $0.001 per share, at a reverse stock split ratio ranging from any whole number between 1-for-8 and 1-for-50, subject to and as determined by our Board of Directors (the “Reverse Stock Split”);
2.To approve the issuance of an aggregate of 4,260,000 shares of the Company’s common stock issuable upon the exercise of warrants to purchase the Company’s common stock, in accordance with Nasdaq Listing Rule 5635(d);
3.To approve one or more adjournments of the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 1 or Proposal 2 at the time of the Special Meeting or in the absence of a quorum.
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-14.35美元,归母净利润-1878.9万美元,同比去年增长37.78%
|
| 2023-11-09 |
财报披露：
美东时间 2023-11-09 盘后发布财报
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-22.08美元,归母净利润-1095.2万美元,同比去年增长57.54%
|
| 2023-06-01 |
详情>>
拆分方案：
每30.0000合并分成1.0000股
|
| 2023-05-04 |
详情>>
业绩披露：
2023年一季报每股收益-0.65美元,归母净利润-511.3万美元,同比去年增长-39.47%
|
| 2023-04-28 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors;
2.Ratify the selection of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.Approve, on and advisory basis, the compensation of our named executive officers;
4.Approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value $0.001 per share, at a reverse stock split ratio ranging from any whole number between 1-for-5 and 1-for-100, subject to and as determined by our Board of Directors;
5.Approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting or in the absence of a quorum;
6.To act on any other matters that may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2023-03-16 |
详情>>
业绩披露：
2022年年报每股收益-67.91美元,归母净利润-3493.3万美元,同比去年增长-244.68%
|
| 2023-01-13 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.85美元,归母净利润-3019.8万美元,同比去年增长-357.75%
|
| 2022-10-27 |
股东大会：
将于2022-11-29召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value $0.001 per share (the “Common Stock”), at a reverse stock split ratio of 1-for-40 (the “Reverse Split Proposal”);
2.To approve one or more adjournments of the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Reverse Split Proposal at the time of the Special Meeting or in the absence of a quorum.
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-1.84美元,归母净利润-2579.6万美元,同比去年增长-480.6%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.27美元,归母净利润-366.6万美元,同比去年增长-62.43%
|
| 2022-04-29 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.Elect two Class III directors;
2.Ratify the selection of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.Approve, for purposes of complying with Nasdaq Listing Rule 5635(a), the issuance of shares of common stock as partial consideration for our acquisition of Cancer Prevention Pharmaceuticals, Inc.;
4.Approve the adjournment or postponement of the Annual Meeting to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve proposal 3;
5.to act on any other matters that may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-03-24 |
详情>>
业绩披露：
2021年年报每股收益-0.87美元,归母净利润-1013.5万美元,同比去年增长-112.56%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.59美元,归母净利润-659.7万美元,同比去年增长-69.68%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-15 |
股东大会：
将于2021-05-25召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors;
2.Ratify the selection of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.Approve, on an advisory basis, the compensation of our named executive officers;
|
| 2020-09-04 |
详情>>
内部人交易：
Schaffer Paul W.共交易2笔
|